论文部分内容阅读
北京大学医学部教授、中国工程院院士庄辉介绍说,在过去几年中,中国在预防和管理乙型肝炎方面取得了显著成绩,乙型肝炎感染率降低,从高流行水平降到了中等流行水平。但是我们仍然面临着慢性乙型肝炎引起的肝硬化和肝癌等严重肝脏庆病带来的挑战,在我国每年近28万人死于肝硬化、肝癌等肝脏相关庆病。最新版中国《慢性乙型肝炎防治指南》(以下简称“指南”)提出的治疗总体目标,即最大限度地长期抑制
Zhu Hui, a professor of Peking University’s medical department and a member of the Chinese Academy of Engineering, said that in the past few years, China has made remarkable achievements in the prevention and management of hepatitis B, with the rate of hepatitis B being reduced from a high prevalence level to a mid-level epidemic level. However, we still face the challenges posed by cirrhosis and liver cirrhosis caused by chronic hepatitis B. In our country, nearly 280,000 people die of liver-related diseases such as cirrhosis and liver cancer each year in our country. The latest version of China’s “Guidelines for the Prevention and Treatment of Chronic Hepatitis B” (hereinafter referred to as the “Guide”) put forward the overall goal of treatment, that is, to maximize long-term inhibition